logo
Plus   Neg
Share
Email

Nektar Publishes Two Manuscripts On Its Immuno-oncology Candidate, Bempeg

Nektar Therapeutics (NKTR), a biopharmaceutical company, published preclinical data on its lead immuno-oncology candidate, NKTR-214, bempegaldesleukin (bempeg), an investigational CD122-preferential interleukin-2 pathway agonist designed to provide activation and proliferation of cancer-killing immune cells. The company said the data showed that bempeg, in combination with immune-based therapies including checkpoint inhibition, antigen-specific vaccination and adoptive cell transfer therapy, enhanced T-cell mediated tumor control.

Bempeg in combination with checkpoint inhibitors and other immune-mediating agents is being evaluated in clinical trials, Nektar Therapeutics noted.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Drugstore chain Walgreens and courier services provider Postmates said they have expanded on-demand delivery to more than 7,000 Walgreens stores nationwide. The companies expect the service will help capitalize on the rising need for home delivery amid the coronavirus pandemic. The expansion will enable consumers in cities across the country to get home delivery of health and wellness items. A growing number of retailers in the U.S. are furloughing their employees as the coronavirus pandemic has resulted in the temporary closure of retail stores nationwide. The store closures came as more people in the U.S. are forced to remain at home to help curtail the spread of COVID-19 by promoting social distancing. Ride-hailing giant Uber Technologies said it is offering 10 million free rides and food deliveries to healthcare workers, seniors, and people in need, amid the surging coronavirus or covid-19 crisis. Across the world, the company aims to work with more cities, food banks, hospitals and others to move what matters, such as getting first responders to work, and food to those who need it.
Follow RTT
>